Dong Seok Kim
NIH, USA
Title: Novel sustained release formulation of Exenatide in the treatment of type 2 Diabetes and neurodegenerative diseases
Biography
Biography: Dong Seok Kim
Abstract
Exenatide, a glucagon like peptide-1(GLP-1) analogue, has been developed and widely used in clinic as a treatment for type 2 diabetes. Accumulating data also suggest that exenatide as well as other Glp-1R agoinists posess therapeutic potential for the neruodegerative disease such as Alzheimer's disease (AD) and Parkinson’s disease (PD) by neuroprotective and neurotrophic mechanisms, which is investigated in several clinical trials for the treatment of neurodegenerative disorders. SmartDepotTM is Peptron’s proprietary technology for the sustained release (SR) microsphere formulations of various agents to provide once weekly or longer dosing regimens. Peptron is currently developing for type 2 diabetes a SR-Exenatide (once every two weeks), PT302, which is evaluated in a phase 2 clinical trial. In addition, the therapeutic potential of Exenatide in neurodegenerative disorders is being evaluated in various disease models such as AD, PD, HD and TBI. Previously, Exenatide, delivered by a micro-osmotic pump, showed a neuroprotective effects in mild TBI (mTBI) animal model. In this study, the pharmaceutically acceptable sustained release (SR) formulation of exenatide, PT340, was examined in the mTBI mice model. mTBI mice displayed deficits in novel object recognition, while PT340-treated mTBI mice performed similar to sham. These data suggest a strong beneficial action of PT-340 in treating mTBI. Convinient dosing regimen of SR-Exenatide will provide additional benefits for the treatment of the neurodegenerative diseases as well as type 2 diabetes: maximizing therapeutic effects, increasing drug compliance, and extending patent coverage.